Journal article icon

Journal article

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?

Abstract:

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating enzyme of hepatic origin which plays a key role in low density lipoprotein (LDL) receptor turnover. Genetic studies have confirmed that those with gain-of-function PCSK9 mutations have increased PCSK9 activity, elevated LDLcholesterol levels and a severe form of familial hypercholesterolaemia, while those with variants leading to reduced PCSK9 have lower LDL-cholesterol and a reduced risk of coronary heart disease. This ha...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1007/s00125-016-4178-y

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Nuffield Department of Population Health
Sub department:
Clinical Trial Service Unit
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Nuffield Department of Population Health
Sub department:
Clinical Trial Service Unit
Role:
Author
Publisher:
Springer Berlin Heidelberg Publisher's website
Journal:
Diabetologia Journal website
Volume:
60
Issue:
3
Pages:
381–389
Publication date:
2016-01-01
Acceptance date:
2016-11-21
DOI:
EISSN:
1432-0428
ISSN:
0012-186X
Source identifiers:
660459
Keywords:
Pubs id:
pubs:660459
UUID:
uuid:457deba6-859b-45a4-b6f3-ea5fa8709576
Local pid:
pubs:660459
Deposit date:
2016-11-21

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP